Effects Of Darbepoetin On Vascular Repair Mechanisms In Kidney Disease The DARBEPC Study

Anemia Clinical Trial

Official title:

Effects Of Darbepoetin On Vascular Repair Mechanisms In Kidney Disease The DARBEPC Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00396123
• Other study ID #: HUM 7825
• Status: Completed
• Phase: N/A
• First received: November 2, 2006
• Last updated: June 1, 2017
• Start date: November 2006
• Est. completion date: July 25, 2008

Study information

• Verified date: June 2017
• Source: University of Michigan
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Humans have cells in their blood stream called endothelial progenitor cells or EPCs. These are thought to be important in keeping blood vessels healthy. People with chronic kidney disease (CKD) have low numbers of these cells. People with cardiovascular (heart and blood vessel) disease also have low numbers. Patients with CKD have more cardiovascular disease then any other group.Erythropoietin is a hormone made by the kidneys. It is essential for making red blood cells and also activates EPCs. It is low in people with kidney disease.

As part of your regular medical care for correcting your low red blood cell count, you will be receiving a medication that acts like erythropoietin. It is called darbepoetin.

The purpose of this study is to see if darbepoetin treatment affects EPC numbers and function.

Description:

The majority of patients with kidney disease, an estimated 20 million adults in the U.S., will die of cardiovascular disease. Further, the risk for cardiovascular events is 2-3 fold higher than in the general population and increases with the severity of renal impairment [1]. Reasons for this accelerated atherosclerotic process are unclear. Recent evidence suggests that endothelial progenitor cells (EPC) are critical to maintaining vascular integrity [2]. Patient populations with low circulating EPCs, including patients with kidney disease, have excess vascular disease burden. The hematopoietic cytokine, erythropoietin, is a key regulator of EPCs and is reduced in patients with kidney disease [3]. Therefore, we hypothesize that supplementation with the erythropoietin analog, darbepoetin, enhances EPC function leading to improvement in vascular repair mechanisms in patients with chronic (CKD).

To begin to explore this hypothesis, we will pursue the following specific aims.

1. Determine the effects of darbepoetin on EPC number in patients with anemia related to CKD

2. Determine the effects of darbepoetin on EPC function in patients with anemia related to CKD

3. Determine the effects of darbepoetin on proangiogenic factors in patients with anemia related to CKD

These studies will expand our understanding and potentially guide therapy aimed at reducing the excess cardiovascular disease burden in high risk populations.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: July 25, 2008
• Est. primary completion date: July 25, 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Enrolled in University of Michigan's Nephrology Anemia Clinic

• 18 years old or older

• Have kidney disease but are not on dialysis

Exclusion Criteria:

• Not enrolled in University of Michigan's Nephrology Anemia Clinic

• Less than 18 years of age

• Hematocrit that is less than 28.5%

• Currently participating in a clinical trial with an intervention

• Planning to change their tobacco use habits during the study period

• Have had dose changes of certain medications for cholesterol or diabetes within one month of study enrollment

• Are currently receiving:

• darbepoetin

• erythopoietin

• medications to lower your immune system

• Have had problems within the last 3 months with:

• Bleeding

• Heart attack or stroke

• Heart or blood vessel procedures

• Are pregnant or lactating

Related Conditions & MeSH terms

• Anemia
• Chronic Kidney Disease
• Kidney Diseases
• Renal Insufficiency, Chronic

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
University of Michigan

Country where clinical trial is conducted

United States,